Palliativ behandling
Palliativ behandling
Sist oppdatert: 21.09.2023
Mer informasjon
Utgiver: Helsedirektoratet
Versjon: 1.0
Tidligere versjoner
Kopier lenke til dette emnet
Kopiert
Foreslå endringer/gi kommentarer
Noen pasienter med muskelinvasiv blærekreft kan ikke gjennomgå radikal behandling, enten fordi sykdommen er for avansert eller fordi pasienten er uegnet pga alder, komorbiditet eller andre forhold. Også et betydelig antall pasienter som har gjennomgått radikalkirurgi eller kurativt rettet strålebehandling vil få lokalt, regionalt eller metastatisk tilbakefall av kreftsykdommen. Disse pasientene vil ha ulike plager, alt etter hvor sykdomstilbakefallet er lokalisert. Det er behov for palliative tiltak mot disse plagene, men felles for disse tiltakene er at det er forholdsvis sparsomt med dokumentasjon, og randomiserte studier er praktisk talt fraværende. Mye er basert på erfaringer og publiserte mindre pasientserier. Oftest vil det bli en helt individuell vurdering av hvilket tiltak som er best for pasienten. En gjennomgang av litteratur for kirurgisk og miniinvasiv behandling for lindring av urologisk relatert symptomer ble publisert av Senter for medisinsk metodevurdering i 2003 (Giercksky et al., 2003).
Referanser
Aass, N., Haugne, D. F., Rosland, J. H., HJordhøy, M., Dønnem, T., Knudsen, A. K. (2015).
Nasjonalt handlingsprogram med retningslinjer for palliasjon i kreftomsorgen. (5 utg.). Oslo: Helsedirektoratet. Hentet IS-2285 fra
https://helsedirektoratet.no/retningslinjer/nasjonalt-handlingsprogram-med-retningslinjer-for-palliasjon-i-kreftomsorgen
Arrizabalaga, M., Extramiana, J., Parra, J. L., Ramos, C., Diaz Gonzalez, R., & Leiva, O. (1987). Treatment of massive haematuria with aluminous salts.
Br The Journal of urology,
60(3), 223-6.
Balar, A. V., Castellano, D., O'Donnell, P. H., Grivas, P., Vuky, J., Powles, T., ... Bellmunt, J. (2017). First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.
The Lancet. Oncology,
18(11), 1483-1492.
Balar, A. V., Galsky, M. D., Rosenberg, J. E., Powles, T., Petrylak, D. P., Bellmunt, J., ... Bajorin, D. F. (2017). Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.
Lancet,
389(10064), 67-76.
Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J. L., Fong, L., ... Bajorin, D. F. (2017). Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.
The New England journal of medicine,
376(11), 1015-1026.
Bellmunt, J., Fougeray, R., Rosenberg, J. E., von der Maase, H., Schutz, F. A., Salhi, Y., ... Choueiri, T. K. (2013). Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO,
24(6), 1466-72.
Bellmunt, J., Theodore, C., Demkov, T., Komyakov, B., Sengelov, L., Daugaard, G., ... von der Maase, H. (2009). Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract.
Journal of Clinical Oncology,
27(27), 4454-61.
Challita-Eid, P. M., Satpayev, D., Yang, P., An, Z., Morrison, K., Shostak, Y., ... Stover, D. R. (2016). Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models.
Cancer research,
76(10), 3003-13.
De Santis, M., Bellmunt, J., Mead, G., Kerst, J. M., Leahy, M., Maroto, P., ... Sylvester, R. (2012). Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986.
Journal of Clinical Oncology,
30(2), 191-199.
Duchesne, G. M., Bolger, J. J., Griffiths, G. O., Trevor Roberts, J., Graham, J. D., Hoskin, P. J., ... Parmar, M. K. (2000). A randomized trial of hypofractionated schedules of palliative radiotherapy in the management of bladder carcinoma: results of medical research council trial BA09.
International journal of radiation oncology, biology, physics,
47(2), 379-88.
Ghahestani, S. M., & Shakhssalim, N. (2009). Palliative treatment of intractable hematuria in context of advanced bladder cancer: a systematic review.
Urology journal,
6(3), 149-56.
Giercksky, K., Grønbech, J. E., Hammelbo, T., Hirshberg, H., Lundar, T., Mjåland, O., Stangeland, L., Søreide, J. A., Trovik, C., Walløe, A., Wahlqvist, R., Wessel, N., Håheim, L. L. (2003).
Bruk av palliativ kirurgi i behandlingen av kreftpasienter. Oslo: Sintef. Hentet SMM-rapport Nr. 8/2003 fra
www.kunnskapssenteret.no/publikasjoner/_attachment/172405?_ts=14855a78a2d
Grimm, M., Bex, A., De Santis, M., Ljungberg, B., Catto, J. W. F., Rouprêt, M., ... Van Poppel, H. (2019). Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019.
European urology,
76(3), 368-380.
Grivas, P., Monk, B. J., Petrylak, D., Reck, M., Foley, G., Guenther, S., ... Moehler, M. (2019). Immune Checkpoint Inhibitors as Switch or Continuation Maintenance Therapy in Solid Tumors: Rationale and Current State.
Targeted oncology,
14(5), 505-525.
Guzzo, T. J., Rogers, C. G., Deng, C. Y., Bivalacqua, T. J., Palapattu, G. S., Bastian, P. J., ... Gonzalgo, M. L. (2008). Outcomes of patients after aborted radical cystectomy for intraoperative findings of metastatic disease.
BJU international,
102(11), 1539-43.
Kamat, A. M., Huang, S. F., Bermejo, C. E., Rosser, C. J., Pettaway, C. A., Pisters, P. W., ... Pisters, L. L. (2003). Total pelvic exenteration: effective palliation of perineal pain in patients with locally recurrent prostate cancer.
The Journal of urology,
170(5), 1868-71.
Leibovici, D., Kamat, A. M., Pettaway, C. A., Pagliaro, L., Rosser, C. J., Logothetis, C., & Pisters, L. L. (2005). Cystoprostatectomy for effective palliation of symptomatic bladder invasion by prostate cancer.
The Journal of urology,
174(6), 2186-90.
Liguori, G., Amodeo, A., Mucelli, F. P., Patel, H., Marco, D., Belgrano, E., & Trombetta, C. (2010). Intractable haematuria: long-term results after selective embolization of the internal iliac arteries.
BJU international,
106(4), 500-3.
Nieuwenhuijzen, J. A., Horenblas, S., Meinhardt, W., van Tinteren, H., & Moonen, L. M. (2004). Salvage cystectomy after failure of interstitial radiotherapy and external beam radiotherapy for bladder cancer.
BJU international,
94(6), 793-7.
Oing, C., Rink, M., Oechsle, K., Seidel, C., von Amsberg, G., & Bokemeyer, C. (2016). Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond-A Comprehensive Review of the Current Literature.
The Journal of urology,
195(2), 254-63.
Oliai, C., Fisher, B., Jani, A., Wong, M., Poli, J., Brady, L. W., & Komarnicky, L. T. (2012). Hyperbaric Oxygen Therapy for Radiation-Induced Cystitis and Proctitis.
International journal of radiation oncology, biology, physics,
84(3), 733-740.
Powles, T., Durán, I., van der Heijden, M. S., Loriot, Y., Vogelzang, N. J., De Giorgi, U., ... Ravaud, A. (2018). Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.
Lancet,
391(10122), 748-757.
Powles, T., Park, S. H., Voog, E., Caserta, C., Valderrama, B. P., Gurney, H., ... Grivas, P. (2020). Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma.
The New England journal of medicine,
383(13), 1218-1230.
Powles, T., Rosenberg, J. E., Sonpavde, G. P., Loriot, Y., Durán, I., Lee, J. L., ... Petrylak, D. P. (2021). Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.
The New England journal of medicine,
384(12), 1125-1135.
Raggi, D., Miceli, R., Sonpavde, G., Giannatempo, P., Mariani, L., Galsky, M. D., ... Necchi, A. (2016). Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO,
27(1), 49-61.
Rosenberg, J. E., Carroll, P. R., & Small, E. J. (2005). Update on chemotherapy for advanced bladder cancer.
The Journal of urology,
174(1), 14-20.
Saylor, P. J., Armstrong, A. J., Fizazi, K., Freedland, S., Saad, F., Smith, M. R., ... Pienta, K. (2013). New and emerging therapies for bone metastases in genitourinary cancers.
European urology,
63(2), 309-20.
Sharma, P., Retz, M., Siefker-Radtke, A., Baron, A., Necchi, A., Bedke, J., ... Galsky, M. D. (2017). Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.
The Lancet. Oncology,
18(3), 312-322.
Stenzl, A., Cowan, N. C., De Santis, M., Kuczyk, M. A., Merseburger, A. S., Ribal, M. J., ... European Association of, U. (2011). Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines.
European urology,
59(6), 1009-18.
Sternberg, C. N., & Vogelzang, N. J. (2003). Gemcitabine, paclitaxel, pemetrexed and other newer agents in urothelial and kidney cancers.
Critical reviews in oncology/hematology,
46 Suppl(Suppl), S105-15.
Sweeney, P., Millikan, R., Donat, M., Wood, C. G., Radtke, A. S., Pettaway, C. A., ... Pisters, L. L. (2003). Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder?.
The Journal of urology,
169(6), 2113-7.
van Helvoirt, R. (2021). Palliativ strålebehandling av blærekreft.
Onkonytt,
(1)
Vogelzang, N. J. (2013). Antiangiogenic agents, chemotherapy, and the treatment of metastatic transitional cell carcinoma.
Journal of Clinical Oncology,
31(6), 670-5.
von der Maase, H., Hansen, S. W., Roberts, J. T., Dogliotti, L., Oliver, T., Moore, M. J., ... Conte, P. F. (2000). Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.
Journal of Clinical Oncology,
18(17), 3068-3077.
von der Maase, H., Sengelov, L., Roberts, J. T., Ricci, S., Dogliotti, L., Oliver, T., ... Arning, M. (2005). Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer.
Journal of Clinical Oncology,
23(21), 4602-8.
Zaghloul, M. S., Boutrus, R., El-Hossieny, H., Kader, Y. A., El-Attar, I., & Nazmy, M. (2010). A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer.
International journal of clinical oncology,
15(4), 382-9.
- Gå til avsnitt
- Referanser
Lukk
